MaxCyte Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 105/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.34.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MaxCyte Inc's Score
Industry at a Glance
Industry Ranking
105 / 208
Overall Ranking
242 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
6.344
Target Price
+309.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
MaxCyte Inc Highlights
StrengthsRisks
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 38.63M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 38.63M.
Overvalued
The company’s latest PE is -3.49, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 82.96M shares, decreasing 17.02% quarter-over-quarter.
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Ticker SymbolMXCT
CompanyMaxCyte Inc
CEOMasoud (Maher)
Websitehttps://www.maxcyte.com/
FAQs
What is the current price of MaxCyte Inc (MXCT)?
The current price of MaxCyte Inc (MXCT) is 1.635.
What is the symbol of MaxCyte Inc?
The ticker symbol of MaxCyte Inc is MXCT.
What is the 52-week high of MaxCyte Inc?
The 52-week high of MaxCyte Inc is 5.200.
What is the 52-week low of MaxCyte Inc?
The 52-week low of MaxCyte Inc is 1.260.
What is the market capitalization of MaxCyte Inc?
The market capitalization of MaxCyte Inc is 174.36M.
What is the net income of MaxCyte Inc?
The net income of MaxCyte Inc is -41.05M.
Is MaxCyte Inc (MXCT) currently rated as Buy, Hold, or Sell?
According to analysts, MaxCyte Inc (MXCT) has an overall rating of Buy, with a price target of 6.344.
What is the Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT)?
The Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT) is -0.430.